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Abstract
Background Identification of patients at risk of deteriora-
tion is essential to guide clinical management in pulmonary
arterial hypertension (PAH). This study aims to provide
a comprehensive overview of well-investigated echocardio-
graphic findings that are associated with clinical deteriora-
tion in PAH.
Methods MEDLINE and EMBASE databases were sys-
tematically searched for longitudinal studies published by
April 2015 that reported associations between echocardio-
graphic findings and mortality, transplant or clinical wors-
ening. Meta-analysis using random effect models was per-
formed for echocardiographic findings investigated by four
or more studies. In case of statistical heterogeneity a sen-
sitivity analysis was conducted.
Results Thirty-seven papers investigating 51 echocardio-
graphic findings were included. Meta-analysis of univari-
able hazard ratios (HRs) and sensitivity analysis showed
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that presence of pericardial effusion (pooled HR 1.70; 95 %
CI 1.44–1.99), right atrial area (pooled HR 1.71; 95 % CI
1.38–2.13) and tricuspid annular plane systolic excursion
(TAPSE; pooled HR 1.72; 95 % CI 1.34–2.20) were the
most well-investigated and robust predictors of mortality or
transplant.
Conclusions This meta-analysis substantiates the clinical
yield of specific echocardiographic findings in the prognos-
tication of PAH patients in day-to-day practice. In particu-
lar, pericardial effusion, right atrial area and TAPSE are of
prognostic value.
Keywords Pulmonary arterial hypertension · Prognosis ·
Echocardiography · Mortality · Non-invasive imaging
Introduction
The ongoing research on pulmonary arterial hypertension
(PAH) has led to increased awareness of the pathophysi-
ological, haemodynamic and clinical consequences of this
devastating disease [1]. Without intervention, progressive
remodelling of the distal pulmonary arteries leads to el-
evated pulmonary vascular resistance, eventually resulting
in right heart failure and death [1, 2]. Fortunately, advances
in therapeutic modalities have greatly improved the survival
and quality of life in patients with PAH [3]. However, the
natural course of the disease varies widely between indi-
viduals, as some patients live for decades while others die
within months of diagnosis [4]. In order to guide optimal
clinical management, it is therefore essential to accurately
monitor disease progression and estimate prognosis in PAH.
Previously reported predictors of mortality include aeti-
ology of PAH, gender and several functional, haemody-
namic and biochemical variables [5–8]. Echocardiogra-
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Fig. 1 PRISMA 2009 flow
diagram
*one study investigated both echocardiographic and CMR findings.
From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-
Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097
For more informaon, visit www.prisma-statement.org
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phy is the most readily available cardiac imaging modality
and is universally used in the follow-up of patients with
PAH. Current literature reports several echocardiographic
findings that may provide important prognostic informa-
tion. The goal of this study is to provide a comprehen-
sive overview of the most thoroughly investigated baseline
echocardiographic findings that are associated with adverse
clinical outcome in PAH. Separately, this study evaluates
the prognostic value of a change in echocardiographic find-
ings during a follow-up period.
Methods
This systematic review was conducted in accordance with
the PRISMA statement [9]. A pre-defined review protocol,
as adopted by this study, can be accessed through PROS-
PERO (registration number: CRD42014009231).
Literature search strategy
A comprehensive systematic search was performed in
MEDLINE (via PubMed interface) and EMBASE elec-
tronic databases on 29 April 2015 using combinations of
all synonyms for: PAH, echocardiography and relevant
clinical outcomes (components of the Dana Point Time To
Clinical Worsening composite endpoint) [1]. A validated
prognostic search filter with the highest sensitivity (98 %)
was added to the search syntax [10]. No language or pub-
lication period restrictions were applied. The full original
search syntax is provided in Supplementary File 1.
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Selection of papers
A flow diagram of the selection process is shown in Fig. 1
[9]. After deduplication, one author performed screen-
ing and selection of articles based on title and abstract,
using the following exclusion criteria: inappropriate study
type (cross-sectional or trial design, reviews, case reports
with < 10 patients, editorials or congress abstracts), non-
clinical data (technical, animal and in-vitro studies), study
population without PAH (e. g. acute pulmonary embolism,
exercise-induced pulmonary hypertension), studies that in-
cluded children < 12 years, and studies that did not relate
echocardiographic findings to clinical outcome. Full-text
screening was performed by two authors; reasons for exclu-
sion are described in Fig. 1. All references of the excluded
reviews and included articles were cross-checked to iden-
tify possible relevant articles missed in the original search
syntax.
Assessment of methodological quality
Study quality was critically appraised using previously de-
veloped criteria for prognostic studies [11]. We assessed
study design, missing data and loss to follow-up (selection
bias), adequate description and measurement of imaging
features and outcome (information bias), reported effect
size, treatment of continuous risk predictors and multivari-
able adjustment for possible confounders.
Data extraction and analysis
Study characteristics and hazard ratios (HRs) for all in-
vestigated echocardiographic findings with accompanying
95 % confidence intervals were extracted using a standard-
ised form. Meta-analysis was performed for all echocar-
diographic findings that were investigated as continuous
parameters by four or more studies, using random effect
models. In order to unify the extracted data to allow more
studies to be pooled, HRs were recalculated to one uniform
clinically applicable number of units change. Heterogene-
ity was assessed using Cochran’s Q test and the I2 statis-
tic. Imaging findings investigated as dichotomous variables
were additionally presented at the bottom of the correspond-
ing forest plots. For all echocardiographic measurements
with significant heterogeneity (I2 > 50 % or Cochran’s Q
p-value < 0.10) a sensitivity analysis was performed by
excluding specific patient subgroups.
If study data were used in multiple papers and the same
echocardiographic findings were evaluated, only the study
with the largest sample size was used to exclude the risk
of using duplicate data in our meta-analysis. The risk of
publication bias was assessed using visual inspection of
funnel plots and Egger’s test.
Results
Search results
The systematic literature search in MEDLINE and EM-
BASE and extensive reference cross-checking retrieved
2,733 potentially relevant records, of which 2,610 were
excluded based on title and abstract (Fig. 1). After full-text
review of the remaining 123 articles, 37 papers were finally
selected [6, 12–47]. Study and patient characteristics of
the included studies are shown in Tab. 1.
The total number of patients per study ranged from 25 to
2,716, with a mean age ranging from 31–61 years (60–98 %
female) and 35–100 % of patients in New York Heart Asso-
ciation (NYHA) class III–IV. Twelve studies included pa-
tients with congenital heart disease (CHD) (6–100 % of
patients) [6, 22, 25, 30, 31, 33, 36, 41–43, 46, 47] and
seven studies included a subset of patients with pulmonary
hypertension group III or IV (< 30 % of total study popula-
tion) [18, 20, 29, 33, 35–37]. The majority of studies used
death or transplant as primary outcome; only five studies
(14 %) used a composite outcome, additionally including
hospitalisation for heart failure [20, 35, 41, 47], need for
a second vasodilator drug or worsening of functional class
[36]. Mean follow-up duration varied between 11 and
53 months, with the primary outcome event occurring in
6–340 patients (10–62 % of study population).
Methodological aspects
In Fig. 2, an overview of the methodological quality of all
included studies is presented. Individual bias assessment
per study is provided in Supplementary File 2. Studies
prospectively included consecutive patients diagnosed with
the disease (43 % of studies) or retrospectively reviewed
echocardiographic images. Information on missing values
and loss to follow-up was not reported in 16 (43 %) and
21 (57 %) of the 37 studies, respectively. It is therefore
important to recognise the possible impact of selection bias
on individual study outcomes.
All studies used right heart catheterisation for the di-
agnosis of PAH in 100 % of the included patients, except
for one study that used right heart catheterisation in 87 %
and echocardiography in 13 % of patients [35]. Definition
and measurement of echocardiographic findings and study
outcome was appropriate and consistent in the majority of
studies, therefore the impact of information bias is assumed
to be small.
Cox regression analysis was performed in all studies;
however large differences for predictors included in the
multivariable analysis were found. Twenty-nine studies per-
formed some form of multivariable adjustment, of which
only 15 adjusted for age and gender. Only nine studies
Neth Heart J (2016) 24:374–389 381
Tab. 1 Study characteristics
Study,
ref
no
Size,
n
Age,
years
Gender,
%
fe-
male
NYHA
class
III–IV,
%
IPAH/
heredi-
tary
Drug/
toxin
PAH-
CTD
Po-PAH PAH-
CHD
WHO
I PAH
(other/not
speci-
fied)
WHO
III
(lung
dis-
ease)
WHO
IV
(CTEPH)
Follow-up
duration,
months
Events,
n (%)
[11] 26 41
[16–70]
69 NR 100 - – – – – – – 24 ± 14 16 (62)
[12] 26 43 ± 17 73 58 100 – – – – – – – NR 6 (23)
[13] 53 45 ± 14 72 70 100 – – – – – – – 35 [NR] 32 (60)
[14] 43 37
[14–67]
70 86 100 – – – – – – – 21 ± 16 12 (28)
[15] 25 38 ± 13 76 100 100 – – – – – – – 12 [0–84] 13 (52)
[16] 81 40 ± 15 73 100 100 – – – – – – – 36 ± 15 41 (51)
[17] 63 55 ± 15 83 70 37 – 38 – – – 21 5 19 [10–22]a 23 (37)
[18] 54 52 ± 11 76 76 100 – – – – – – – 50 [NR] 12 (22)
[19] 50 46 ± 13 78 42 46 – 22 – – 4 – 28 14 [12–18] 19 (38)
[6] 2716 50 ± 17 79 54 49 5 24 5 12 5 – – 17 [0–24] 340 (13)
[20] 76 61 ± 11 84 53 – – 100 – – – – – 36
[NR–113]
42 (55)
[21] 32 53 ± 16 66 91 69 16 6 – 9 – – – 21 [NR] 17 (53)
[22] 59 46 ± 16 63 66 100 – – – – – – – 52 [28–79]a 23 (39)
[23] 72 52 ± 16 72 76 100 – – – – – – – 38 [14–71]a 22 (31)
[24] 484 52 ± 15 75 71 56 – 24 11 9 – – – 38 [16–60] 264 (55)
[25] 50 61 ± 11 98 70 – – 100 – – – – – 16 [9–39] 25 (50)
[26] 80 56 ± 14 76 72 43 – 41 10 – 6 – – 24 [NR] 33 (41)
[27] 95 31 ± 10 64 56 100 – – – – – – – 21 ± 15 27 (28)
[28] 57 52 ± 14 28 100 63 – 18 11 – 5 – 3 25 ± 29 29 (51)
[29] 181 39 ± 13 67 67 – – – – 100 – – – 16 [7–46] 19 (10)
[30] 154 54 ± 9 84 NR 46 1 40 5 6 3 – – 36 [17–71]a 71 (46)
[31] 61 48 ± 18 84 69 100 – – – – – – – NR NR
[32] 142 59 ± 15 65 44 31 9 19 4 9 1 – 27 11 [6–39] 28 (20)
[33] 577 53 ± 15 75 70 – – – – – 100 – – 57 ± 50 NR
[34] 406 59 ± 16 65 46 – – – – – 74 14 12 16 [8–20]a 73 (18)
[35] 32 39 ± 15 69 59 22 – 16 – 53 – – 9 14 [8–21] 15 (47)
[36] 124 54 ± 16 70 92 – – – – – 84 – 16 36 ± 22 31 (25)
[37] 71 57 ± 14 76 75 46 – 41 6 – 7 – – 24 [NR] 20 (28)
[38] 50 56 ± 12 84 72 42 – 38 14 – 6 – – 48 [NR] NR
[39] 102 54 ± 16 84 NR 47 – 24 – – 29 – – 44 [22–79]a 43 (42)
[40] 37 46 ± 14 76 35 65 – 5 – 24 5 – – 16 [13–18]a 7 (19)
[41] 48 44 ± 14 83 100 67 – 21 6 6 – – – 53 [21–80]a 18 (38)
[42] 91 42 ± 14 60 73 – – – – 100 – – – 46 [4–64] 24 (26)
[43] 79 48
[24–65]
66 92 92 – 8 – – – – – NR [12–92] 27 (34)
[44] 121 60 ± 14 66 63 39 – 36 18 – 6 – – 37 ± 36 49 (40)
[45] 200 54 ± 15 71 50 47 1 33 7 12 – – – 43 ± 31 106 (53)
[46] 51 60 ± 15 73 71 33 – 55 6 6 – – – 36 ± 24 8 (16)
CHD congenital heart disease, CTD connective tissue disease, CTEPH chronic thromboembolic pulmonary hypertension, HF heart failure,
IPAH idiopathic pulmonary arterial hypertension, NYHA New York Heart Association, PAH pulmonary arterial hypertension, PH pulmonary
hypertension, SD standard deviation, NR not reported, WHO World Health Organization. ainterquartile range, otherwise reported as median
[range] or mean ± SD
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Fig. 2 Methodological quality
of the included studies. Method-
ological quality of the included
studies was assessed on the
following domains of potential
bias: completeness of data (se-
lection bias), standardisation
of prognostic factors and study
outcome (information bias) and
statistical calculation of effect
size (study outcome)
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(24 %) used more than ten events per predictor. Because of
this large variety between studies and overall poor method-
ological quality of multivariable adjustment, it was chosen
to present only the univariable HRs in forest plots.
Prognostic value of baseline echocardiographic findings
In 37 studies, in total 51 echocardiographic findings were
evaluated (Supplementary File 3). Meta-analysis was per-
formed for ten echocardiographic findings that were suit-
able for pooling of results among four or more studies:
presence of pericardial effusion, right atrial area, right ven-
tricular (RV) pressure estimates, severity of tricuspid regur-
gitation, estimated right atrial pressure, left ventricular (LV)
eccentricity index (Fig. 3a), tricuspid annular plane systolic
excursion (TAPSE), RV fractional area change, Tei index
(an index of RV myocardial performance) and RV free wall
longitudinal peak systolic strain (LPSS) (Fig. 3b).
Although not included in the meta-analysis, RV end-di-
astolic basal dimension [24, 30, 33, 36] or area [17, 25,
36, 37] and tissue Doppler velocity (S’) of the tricuspid
valve annulus [30, 33, 35, 36, 41] were investigated by sev-
eral studies and could be of prognostic importance. Less
investigated echocardiographic measurements such as pul-
monary artery capacitance [19, 35], several strain values
[27, 38, 44], RV diastolic dysfunction [12, 20, 30], LV
end-diastolic volume [23], systolic pulmonary artery pres-
sure increase during exercise [37] and RV load adaptation
index [44] seem promising but require further evaluation.
Serial echocardiographic evaluation
Five studies included in this review investigated the prog-
nostic value of a change in echocardiographic findings dur-
ing a follow-up period, rather than their absolute baseline
values, as indicated in Supplementary File 3 [39, 42, 44,
46, 47]. Patients with ≥ 5 % improvement in RV free wall
LPSS on PAH treatment at 6 ± 2 months follow-up had
a significantly reduced mortality risk at four years (HR
0.13; 95 % CI 0.03–0.50) [39]. Tonelli et al. showed that
overall mortality was associated with a 10 % increase in RV
end-diastolic area (HR 1.37; 95 % CI 1.08–1.75), tricuspid
regurgitation velocity (HR 1.72; 95 % CI 1.12–2.70) and
difference in qualitative RV function (HR per unit of im-
provement 0.55; 95 % CI 0.31–0.96) at one-year follow-up
[42]. Sano et al. recently reported that a mid-term change
in RV end-systolic area (HR 0.92; 95 % CI 0.86–0.98) and
in right atrial area (HR 0.95; 95 % CI 0.92–0.99) were sig-
nificantly related to long-term outcome [47]. In addition,
changes in RV load-adaptation index and pericardial effu-
sion have been associated with clinical outcomes in PAH
[44, 46].
Risk of bias assessment
Heterogeneity statistics (Cochran’s Q and I2) are presented
in the corresponding forest plots in Fig. 3a and b. For
all echocardiographic measurements with significant statis-
tical heterogeneity, we performed a sensitivity analysis to
evaluate possible sources for heterogeneity (Tab. 2). We
excluded specific studies (< 70 % in NYHA class III–IV,
< 100 % PAH, inclusion of CHD, < 50 % on PAH medi-
cation at baseline, other endpoints than mortality or trans-
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Presence of pericardial effusion
0.1 1 10
= 42%)2 Total (Q = 25.7, I
Shimony 2013
Ciarka 2010
Badagliacca 2012
Austin 2015
Fine 2013
Raymond 2002
Forfia 2006 (grade 0-4)
Campo 2010
Eysmann 1989 (grade 0-3)
Kane 2011
Fenstad 2013
Ernande 2013
Benza 2010
Mathai 2011 (grade 0-4)
Ghio 2010
Miyamoto 2000 (grade 0-2) 0.37 (0.02- 5.53)
0.79 (0.18- 3.40)
1.11 (0.75- 1.64)
1.35 (1.10- 1.80)
1.47 (0.62- 3.47)
1.50 (1.23- 1.83)
1.54 (1.17- 2.02)
1.66 (0.99- 2.78)
1.69 (0.90- 3.32)
1.69 (1.12- 2.54)
2.08 (1.12- 3.86)
2.19 (1.51- 3.09)
2.49 (1.34- 4.63)
2.97 (1.25- 7.06)
3.49 (1.12- 10.9)
6.85 (2.60- 18.1)
1.70 (1.44-1.99)
p< 0.001
Hazard ratio
0.1 1 10
Grunig 2013 (>20 cm2)
Austin 2015 (>18 cm2)
Kane 2011 (severe enlargement)
Ernande 2013 (>14 cm2/m)
Schuuring 2014 (>25 cm2)
 = 55%)2Total (Q = 8.9, I
Forfia 2006 (cm2/m)
Moceri 2012 (cm2)
Mathai 2011 (cm2/m)
Bustamante 2002 (cm2)
Raymond 2002 (cm2/m)
Right atrial area (per 5 cm 2 increase)
1.33 (1.06- 1.66)
1.61 (1.20- 2.16)
1.69 (1.15- 2.48)
1.89 (1.39- 2.59)
2.93 (1.74- 4.94)
1.71 (1.38-2.13)
p< 0.001
1.10 (0.40- 3.20)
1.17 (0.44- 3.08)
1.84 (1.39- 2.41)
2.60 (1.32- 5.14)
10.20 (1.30- 76.92)
Hazard ratio
0.1 1 1
0
Cho 2014 (RVSP >73 mmHg)
Ernande 2013 (SPAP >78 mmHg)
Grunig 2013 (SPAP >95 mmHg)
= 76%)2 Total (Q = 25.1, I
Mahapatra 2006 (RVSP)
Mathai 2011 (RVSP)
Fine 2013 (SPAP)
Ciarka 2010 (RVSP)
Giusca 2013 (SPAP)
Raymond 2002 (RVSP)
Ghio 2010 (RVSP)
 RV  pressure estimates (per 10 mmHg increase)
0.90 (0.74- 1.10)
1.00 (0.76- 1.32)
1.00 (0.74- 1.35)
1.10 (0.95- 1.28)
1.30 (1.22- 1.39)
1.81 (1.20- 2.73)
1.97 (1.23- 3.14)
1.18 (1.01-1.38)
p= 0.043
0.34 (0.15- 0.75)
1.05 (0.50- 2.21)
1.43 (0.32- 6.48)
Hazard ratio
0.1 1 10
=39%)2Total (Q=9.8, I
Ghio 2010 (moderate/severe)
Kane 2011 (severe)
Austin 2015 (moderate/severe)
Forfia 2006 (grade 0-3)
Bustamante 2002 (grade 0-3)
Yeo 1998 (grade 0-4)
Raymond 2002 (TR/RA per 0.2)
TR severity
1.37 (0.96- 1.97)
1.67 (0.67- 4.15)
2.52 (1.01- 6.30)
2.59 (1.39- 4.81)
2.62 (1.34- 5.13)
2.82 (1.94- 3.98)
3.11 (1.20- 9.48)
2.20 (1.64-2.95)
p<0.001
Hazard ratio
0.1 1 10
=76%)2Total (Q=20.7, I
Moceri 2012 (>15 mmHg)
Austin 2015 (>15 mmHg)
Fine 2013 (>15 mmHg)
Ghio 2010 (>15 mmHg)
Kane 2011 (>10 mmHg)
Mahapatra 2006 (>15 mmHg)
Estimated RA pressure
0.90 (0.52- 1.58)
1.95 (1.47- 2.63)
2.94 (1.19- 7.26)
3.32 (2.37- 4.62)
4.20 (1.81- 9.77)
4.52 (1.73- 11.82)
2.45 (1.56-3.85)
p<0.001
Hazard ratio
0.1 1 10
1.7)≥Ghio 2010 (ED 
1.4)≥Ernande 2013 (ED 
0.81)≥Cho 2014 (ES 
 = 0%)2Total (Q = 3.0, I
Forfia 2006
Mathai 2011
Raymond 2002
Miyamoto 2000
LV eccentricity index
1.60 (0.32- 8.10)
2.10 (1.27- 3.49)
5.39 (1.42- 20.4)
6.14 (1.03- 36.48)
2.43 (1.57-3.75)
p<0.001
0.26 (0.05- 1.42)
1.65 (0.75- 3.65)
3.68 (1.55- 8.74)
Hazard ratio
TAPSE (per 5 mm decrease)
0.1 1 1
0
14 mm)≤Schuuring 2014 (
19 mm)≤Grunig 2013 (
17 mm)≤Ernande (
14 mm)≤Cho 2014 (
 = 77%)2Total (Q = 26.1, I
Forfia 2006
Moceri 2012
Mathai 2011
Giusca 2013
Fine 2013
Ghio 2010
Dandel 2014 1.20 (1.09- 1.31)
1.60 (1.03- 2.49)
1.69 (1.43- 2.00)
1.89 (1.04- 3.44)
2.01 (1.19- 3.37)
2.50 (1.52- 4.11)
2.54 (1.07- 6.01)
1.72 (1.34-2.20)
p<0.001
0.47 (0.09- 2.43)
2.62 (1.10- 6.19)
2.83 (1.17- 6.85)
3.50 (1.40- 8.60)
Hazard ratio
RV fractional area change (per 5% decrease)
0.1 1 1
0
Shimony 2012 (no RV dysf)
Austin 2015 (<35%)
Kane 2011 (no RV dysf)
 = 60%)2Total (Q = 10.1, I
Giusca 2013
Forfia 2006
Fine 2013
Raymond 2002
Mathai 2011 1.05 (0.86- 1.29)
1.08 (0.88- 1.32)
1.15 (0.99- 1.35)
1.52 (1.15- 2.00)
1.89 (1.24- 2.90)
1.23 (1.04-1.44)
p=0.039
1.45 (1.23- 1.87)
2.32 (1.18- 4.53)
3.03 (0.86- 11.11)
Hazard ratio
0.1 1 1
0
0.47)≥Cho 2014 (
 = 73%)2Total (Q = 22.3, I
Shimony 2012
Ghio 2010
Mahapatra 2006
Tei 1996
Yeo 1998
Fine 2013
Kane 2011
Tei index (per 0.1 increase)
1.06 (1.01- 1.11)
1.25 (1.16- 1.35)
1.30 (1.09- 1.56)
1.30 (1.00- 1.70)
1.66 (1.05- 2.60)
2.61 (0.52- 13.03)
3.25 (0.24- 44.90)
1.23 (1.09-1.40)
p=0.001
1.02 (0.23- 4.59)
Hazard ratio
0.
1 1 10
-18.7%)≥Ernande 2013 (
=0%)2Total (Q=3,0, I
Sachdev 2011
Sano 2015
Giusca 2013
Fine 2013
RV free wall longitudinal peak systolic strain (per 5% decrease)
1.65 (1.46- 1.88)
2.10 (1.23- 3.60)
2.16 (1.20- 3.91)
2.40 (1.45- 4.21)
1.72 (1.53-1.93)
p< 0.001
2.17 (0.97- 4.84)
Hazard ratio
a
b
Fig. 3 a Prognostic value of echocardiographic findings investigated in four or more studies. b Prognostic value of echocardiographic measure-
ments of RV function investigated in four or more studies
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Fig. 4 Prognostic value of pericardial effusion, TAPSE and right atrial area
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Tab. 2 Sensitivity analysis for all echocardiographic measurements with significant statistical heterogeneity (I2 > 50 % or p-value < 0.10) in
specific study subgroups
No. of
studies
HR 95 % CI p-value I2, % Cochran’s Q
(p-value)
Presence of pericardial effusion 16 1.70 1.44–1.99 < 0.001 42 25.7 (0.041)
> 70 % NYHA class III–IV 8 1.56 1.31–1.86 < 0.001 23 9.0 (0.249)
100 % PAH 12 1.62 1.34–1.96 < 0.001 45 20.1 (0.045)
Exclusion of CHD 12 1.81 1.45–2.25 < 0.001 49 21.5 (0.028)
> 50 % on PAH medication/NR 10 1.86 1.40–2.47 < 0.001 60 22.3 (0.008)
Mortality/transplant as outcome 15 1.64 1.39–1.94 < 0.001 38 22.5 (0.069)
Right atrial area, per 5 cm2 increase 5 1.71 1.38–2.13 < 0.001 55 8.9 (0.063)
> 70 % NYHA class III–IV 4 1.69 1.29–2.21 < 0.001 61 7.8 (0.051)
100 % PAH 4 1.56 1.33–1.84 < 0.001 17 3.6 (0.306)
Exclusion of CHD 4 1.69 1.29–2.21 < 0.001 61 7.8 (0.051)
> 50 % on PAH medication/NR 3 1.77 1.17–2.68 0.007 74 7.7 (0.021)
Mortality/transplant as outcome 5 1.71 1.38–2.13 < 0.001 55 8.9 (0.063)
RV pressure, per 10 mmHg increase 7 1.18 1.01–1.38 0.043 76 25.1 (< 0.001)
> 70 % NYHA class III–IV 4 1.33 1.00–1.77 NS 72 10.9 (0.012)
100 % PAH 5 1.20 0.95–1.52 NS 75 15.8 (0.003)
Exclusion of CHD 5 1.26 1.00–1.59 NS 81 20.6 (< 0.001)
> 50 % on PAH medication/NR 5 1.19 1.02–1.38 0.024 66 11.8 (0.019)
Mortality/transplant as outcome 5 1.20 0.95–1.52 NS 75 15.8 (0.003)
Right atrial pressure, > 15 mmHg 6 2.45 1.56–3.85 < 0.001 76 20.7 (< 0.001)
> 70 % NYHA class III–IV 2 1.38 0.65–2.92 NS 82 5.7 (0.017)
100 % PAH 6 2.45 1.56–3.85 < 0.001 76 20.7 (< 0.001)
Exclusion of CHD 4 2.41 1.16–4.98 0.018 82 17.0 (< 0.001)
> 50 % on PAH medication/NR 0 – – – – –
Mortality/transplant as outcome 5 2.28 1.33–3.92 0.003 72 14.2 (0.007)
TAPSE, per 5 mm decrease 7 1.72 1.34–2.20 < 0.001 77 26.1 (< 0.001)
> 70 % NYHA class III–IV 3 1.63 1.01–2.63 0.047 69 6.5 (0.039)
100 % PAH 4 1.67 1.15–2.44 0.007 77 12.8 (0.005)
Exclusion of CHD 5 1.58 1.22–2.06 < 0.001 79 18.7 (< 0.001)
> 50 % on PAH medication/NR 4 3.24 1.92–5.45 < 0.001 0 1.2 (0.756)
Mortality/transplant as outcome 5 1.76 1.22–2.52 0.002 74 15.4 (0.004)
RV FAC, per 5 % decrease 5 1.23 1.04–1.44 0.039 60 10.1 (0.039)
> 70 % NYHA class III–IV 3 1.18 0.96–1.44 NS 60 5.0 (0.080)
100 % PAH 2 1.06 1.04–1.09 < 0.001 0 0.0 (0.863)
Exclusion of CHD 4 1.16 1.02–1.32 0.026 41 5.0 (0.168)
> 50 % on PAH medication/NR 5 1.23 1.04–1.44 0.039 60 10.1 (0.039)
Mortality/transplant as outcome 3 1.18 0.96–1.44 NS 60 5.0 (0.080)
Tei index, per 0.1 unit increase 7 1.23 1.09–1.40 0.001 73 22.3 (0.001)
> 70 % NYHA class III–IV 3 1.22 0.99–1.51 NS 76 8.3 (0.016)
100 % PAH 6 1.25 1.05–1.48 0.012 58 12.0 (0.035)
Exclusion of CHD 5 1.46 1.24–1.72 < 0.001 0 2.3 (0.677)
> 50 % on PAH medication/NR 2 1.25 1.16–1.35 < 0.001 0 0.5 (0.775)
Mortality/transplant as outcome 6 1.25 1.05–1.48 0.012 58 12.0 (0.035)
CHD congenital heart disease, CI confidence interval, FAC fractional area change, HR hazard ratio, NR not reported, NS non-significant,
NYHA New York Heart Association, PAH pulmonary arterial hypertension, RV right ventricular, TAPSE tricuspid annular plane systolic excursion
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plant used) to investigate whether this impacted the pooled
HR. For presence of pericardial effusion, right atrial area
and TAPSE, sensitivity analysis did not change the overall
conclusions. These results can therefore be regarded with
a higher degree of certainty (Fig. 4).
No sensitivity analysis was performed for severity of tri-
cuspid regurgitation, LV eccentricity index and RV free wall
LPSS; however the forest plots show that especially tricus-
pid regurgitation severity and LV eccentricity index have
relatively large standard errors, and thus provide imprecise
risk estimations.
A combination of visual assessment of funnel plots and
Egger’s test provided statistical evidence of publication bias
for TAPSE (p = 0.026), right atrial area (p = 0.027) and the
Tei index (p = 0.076 and based on the funnel plot). This
may indicate that studies with a positive result are overrep-
resented, subsequently leading to a relative overestimation
of the pooled HR in the meta-analysis.
Discussion
To our knowledge, this is the first systematic review and
meta-analysis on the prognostic value of specific echocar-
diographic findings in patients with PAH. Among 51
echocardiographic findings investigated in 37 studies,
meta-analysis and additional sensitivity analysis showed
that presence of pericardial effusion, right atrial area and
TAPSE were the most robust predictors of mortality or
transplant in patients with PAH.
Right ventricular decompensation
Most deaths in patients with PAH are due to right heart fail-
ure [7]. Once the right ventricle starts to fail, it is no longer
able to overcome the high pulmonary arterial pressures.
This will cause a progressive rise in RV diastolic pressure
and right atrial pressure, generally accompanied by right
atrial enlargement. It is thought that elevated right atrial
pressure causes impaired lymphatic and venous drainage,
subsequently leading to pericardial fluid accumulation [17].
These insights into the mechanistic course tilting a stable
PAH state towards death clearly explain why pericardial ef-
fusion, right atrial area, estimated right atrial pressure and
RV dysfunction measured on echocardiography are associ-
ated with mortality in PAH.
Studies investigating RV function and right atrial pres-
sure as assessed with other diagnostic modalities, such
as cardiac magnetic resonance imaging and right heart
catheterisation, report comparable findings [6, 7, 48, 49].
However, as echocardiography is more widely applied,
non-invasive and less expensive, it is more suitable for the
evaluation of PAH patients in day-to-day practice.
Serial measurements
The majority of the included studies investigated the prog-
nostic value of baseline imaging findings, evaluated at the
time of diagnosis. Complementary information on changes
in haemodynamic, functional and biochemical variables
may better reflect an individual’s response to PAH-targeted
therapy – or progression of disease [50]. Interestingly,
although the first study included in this review originates
from 1989, serial echocardiographic evaluation in PAH has
only recently gained scientific attention, as Hardegree and
colleagues were the first ones to publish on this topic in
2013 [12, 39]. Thus far, changes in pericardial fluid accu-
mulation, right atrial area, tricuspid regurgitation velocity,
RV free wall LPSS and qualitative RV function, RV dimen-
sions and RV load-adaptation index have been associated
with clinical outcomes in PAH [39, 42, 44, 46, 47]. This
is in line with the conclusions reached by the international
working group of Vonk-Noordegraaf et al., who stated that
changes in RV imaging parameters after treatment reflect
altered exercise capacity and predict subsequent survival
[51]. Advantages of echocardiography over more expen-
sive or invasive imaging modalities become especially
important in the serial evaluation of individual patients.
Heterogeneity
PAH prognosis depends largely on the underlying aetiol-
ogy, as the right ventricle can show rapid deterioration after
initial diagnosis in patients with idiopathic or connective
tissue disease-PAH, while it may cope successfully with
pressure overload for decades in patients with congenital
heart disease [4, 6]. Still, most studies in this review in-
vestigated the World Health Organisation (WHO) group I
PAH as a whole. Moreover, some studies in this review
additionally included small subsets (< 30 %) of patients
with WHO group III (pulmonary hypertension due to lung
disease) or IV (chronic thromboembolic pulmonary hyper-
tension), which further increases the heterogeneity of the
study population. The heterogeneity of pulmonary hyper-
tension aetiologies among studies in this review likely plays
a major role in the observed variation between the reported
study results. Along the same line, disease severity and
changing available treatment options over time likely con-
tribute to this observed heterogeneity across studies. We
therefore conducted a sensitivity analysis in which we ex-
cluded studies with other than WHO group I PAH, patients
with CHD, < 70 % patients in NYHA class III–IV (thus in-
vestigating a sicker patient population) or < 50 % on PAH
medication (representing other available treatment options).
Importantly, this clearly reduced the statistical heterogene-
ity in specific study subgroups; however the overall conclu-
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sions for presence of pericardial effusion, right atrial area
and TAPSE remained unchanged.
Study limitations
We presented only univariable HRs in this study, because of
the large variety between studies in which multivariable ad-
justment was performed (regarding the type and number of
predictors per event used). Second, formal tests for publica-
tion bias retrieved significant results for the variables right
atrial area, TAPSE and Tei index. Theoretically, publica-
tion bias may cause underreporting of non-significant HRs,
leading to a relative overestimation of the pooled HRs. Ex-
act results of the random effect models as presented in this
review should be therefore interpreted with caution.
Clinical implications
In order to adequately expand PAH-specific therapy and
timely list patients for transplantation, accurate prognosti-
cation is highly important. The data in this review imply
that especially pericardial effusion, enlarged right atrial area
and decreased TAPSE are useful echocardiographic mark-
ers to predict mortality or transplantation. This is largely
concordant with the 2015 European Society of Cardiology/
European Respiratory Society Guidelines for the diagnosis
and treatment of pulmonary hypertension, in which right
atrial area and pericardial effusion are recommended as de-
terminants of prognosis [2]. Controversy continues to exist
about the use of TAPSE; it has been suggested that progres-
sive RV dysfunction is associated with a decline in TAPSE
until a certain floor effect is reached [52]. Of note, con-
sidering the multi-faceted nature of this disease, accurate
prognostication should always be based on a combination
of haemodynamic, functional, biochemical and echocardio-
graphic findings, and should not rely on just one single
parameter according to the current guidelines [2].
Conclusions
This meta-analysis substantiates the clinical yield of spe-
cific echocardiographic findings in the prognostication of
PAH patients in day-to-day practice. Although accurate
prognostication should not rely on just one single param-
eter, presence of pericardial effusion, enlarged right atrial
area and decreased TAPSE are the most firmly established
echocardiographic tools that can be of important additional
value.
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